Skip to search formSkip to main contentSkip to account menu

CA 19-9 measurement

Known as: CA 19-9 assay, CA-19-9 Measurement, Cancer Antigen 19-9 Measurement 
A test that measures the level of CA 19-9 in the blood. CA 19-9 is a tumor marker released into the bloodstream from both cancer cells and normal… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (1)

Antigens, Tumor-Associated, Carbohydrate
CA-19-9 AntigenCDISC SDTM Laboratory Test Terminology by CodeCDISC SDTM Laboratory Test Terminology by NameClinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Enhanced Discrimination of Malignant from Benign Pancreatic Disease by Measuring the CA 19-9 Antigen on Specific Protein Carriers
The CA 19-9 assay detects a carbohydrate antigen on multiple protein carriers, some of which may be preferential carriers of the… 
Highly Cited
2009
Highly Cited
2009
Follow-Up Study of K-ras Mutations in the Plasma of Patients With Pancreatic Cancer: Correlation With Clinical Features and Carbohydrate Antigen 19-9
Objective: We followed up the presence of Kirsten rat sarcoma (K-ras) mutations in plasma DNA and assessed its clinical value in… 
2002
2002
The correlation of serum carbohydrate antigen 19-9 with benign hydronephrosis.
Highly Cited
2001
Highly Cited
2001
CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU…
BACKGROUND There have been contradictory reports on the benefit of CEA and CA 19-9 measurements in patients with metastatic… 
Highly Cited
1996
Highly Cited
1996
Tumor markers in patients with pancreatic carcinoma
Tumor markers are putative prognostic indicators for patients with carcinoma, but have not heretofore been evaluated in patients… 
1993
1993
Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
UNLABELLED The aims of this study were to (1) evaluate the diagnostic utility of a new tumor marker, TPS, with respect to TPA and… 
Highly Cited
1988
Highly Cited
1988
The evaluation of CA 19‐9 antigen level in the early detection of pancreatic cancer: A prospective study of 866 patients
To establish if CA 19‐9 could detect early pancreatic cancer, we measured its serum concentration in 866 patients admitted for… 
Highly Cited
1987
Highly Cited
1987
Serum CA 19‐9 in the postsurgical follow‐up of patients with pancreatic cancer
In the last few years serum CA 19‐9 has been shown to be a highly sensitive marker of pancreatic adenocarcinoma. This study… 
1986
1986
CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
Levels of a new carbohydrate antigen CA 19-9, which is a monosialoganglioside identified by a monoclonal antibody raised against… 
Highly Cited
1985
Highly Cited
1985
A clinical evaluation of carbohydrate antigen 19‐9 and carcinoembryonic antigen in patients with pancreatic carcinoma
We have studied serum carbohydrate antigen 19‐9 (CA19‐9) and carcinoembryonic antigen (CEA) in 221 persons to assess their… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)